Welcome to our dedicated page for China Sxt Pharmaceuticals news (Ticker: SXTC), a resource for investors and traders seeking the latest updates and insights on China Sxt Pharmaceuticals stock.
China SXT Pharmaceuticals Inc (SXTC) specializes in research-driven Traditional Chinese Medicine Pieces (TCMP) designed for modern healthcare applications. This news hub provides investors and industry stakeholders with essential updates about the company’s financial performance, product innovations, and strategic developments.
Access authoritative reporting on quarterly earnings, regulatory milestones, and manufacturing advancements. Our curated collection features:
• Financial disclosures including earnings reports and SEC filings
• Product development updates across advanced TCMP formulations
• Strategic partnerships with healthcare institutions and distributors
• Regulatory compliance news affecting pharmaceutical operations
Bookmark this page for real-time updates on SXTC’s progress in blending traditional medicinal practices with contemporary manufacturing standards. Monitor critical developments through verified press releases and market analyses.
China SXT Pharmaceuticals (SXTC), a specialty pharmaceutical company focused on Traditional Chinese Medicine Pieces (TCMPs), has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received confirmation from Nasdaq on March 13, 2025, that it has met the minimum bid price of $1.00 per share for 10 consecutive business days.
The compliance issue arose when SXTC received a notification on October 3, 2024, for failing to maintain the required minimum bid price. To address this, the company implemented a 1-for-8 share consolidation on February 25, 2025. Following this action, SXTC maintained the required bid price from February 25 to March 12, 2025, successfully resolving the Nasdaq listing deficiency.
China SXT Pharmaceuticals (SXTC) has announced a 1-for-8 share consolidation effective February 25, 2025, aimed at regaining compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company must maintain a closing bid price above $1.00 for at least ten consecutive trading days by April 1, 2025, to maintain its Nasdaq listing.
The consolidation means every eight ordinary shares will automatically combine into one share, with fractional shares rounded up. All outstanding stock options, warrants, and other rights will be adjusted proportionately. The company will continue trading under the symbol 'SXTC' with a new CUSIP number G2161P157.
Failure to meet the minimum bid requirement could result in delisting from Nasdaq, potentially causing significant adverse effects on the company's securities' value and liquidity.
China SXT Pharmaceuticals (NASDAQ: SXTC) has received a notification from Nasdaq on October 3, 2024, stating that the company no longer meets the minimum bid price requirements. SXTC's ordinary shares have been below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has until April 1, 2025, to regain compliance by maintaining a closing bid price of at least $1 for a minimum of 10 consecutive business days. If SXTC fails to meet this requirement, it may be eligible for an additional 180-day compliance period, provided it meets other listing standards and expresses intention to cure the deficiency, possibly through a reverse stock split.
On November 3, 2022, China SXT Pharmaceuticals, Inc. (SXTC) received a notification from Nasdaq indicating that its ordinary shares have been below the $1.00 minimum bid price for 30 consecutive business days. Although this notification does not immediately affect its listing, the company has until May 2, 2023, to regain compliance. If compliance is not met, the company may be eligible for an additional 180 days, potentially requiring a reverse stock split. Founded in 2005, China's SXT focuses on developing and marketing traditional Chinese medicine.
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) announced a 1-for-20 reverse stock split effective May 17, 2022, following board approval on May 10, 2022. Shareholders will receive one new share for every twenty they hold, reducing the total shares outstanding from approximately 40.6 million to about 2.03 million. The company aims for its share price to increase to roughly twenty times the pre-split price, though it cannot guarantee the market will maintain this price level. The reverse split will also adjust outstanding stock options and restricted shares.
China SXT Pharmaceuticals, Inc. (SXTC) announced a securities purchase agreement to issue a convertible promissory note worth $2,804,848.00 to Streeterville Capital, LLC. The 12-month note will carry a 6% annual interest rate, with conversion options starting 90 days post-issuance at an initial price of $0.30. The company plans to utilize the proceeds for general corporate purposes, including working capital. This transaction is expected to close around March 16, 2022, pending customary conditions.
China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) successfully completed a $4.1 million underwritten public offering of ordinary shares, including the over-allotment. Aegis Capital Corp. acted as the sole bookrunner for this offering. Founded in 2005 and headquartered in Jiangsu Province, China, the company specializes in the research and development of traditional Chinese medicine pieces, facilitating their marketing and sales to the market. The funds raised are expected to support further growth initiatives.
